ArticleChinese medicine2026
Qishen Granules attenuate adverse ventricular remodeling in chronic heart failure by promoting Legumain/Arg1/Rac1-mediated efferocytosis of resident cardiac macrophages.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundVentricular remodeling is a key pathological feature of chronic heart failure (CHF). Following myocardial infarction (MI), impaired macrophage efferocytosis sustains cardiac inflammation, disrupts tissue repair, and accelerates adverse remodeling and dysfunction. Qishen Granules (QSG) is a classical traditional Chinese medicine formulation used in the clinical treatment of heart failure. However, its regulatory effects on efferocytosis in resident cardiac macrophages (RCMs) remain unclear. PURPOSE: This study aimed to elucidate the molecular mechanisms by which QSG regulates Legumain-mediated efferocytosis in RCMs and to identify the key bioactive compounds.
methodsA mouse model of post-MI heart failure was established via ligation of the left anterior descending coronary artery. The therapeutic effects of QSG were evaluated in isolated RCMs obtained using magnetic-activated cell sorting. Mechanistic investigations were conducted using transcriptomic analysis, network pharmacology, live-cell imaging, and siRNA-mediated gene silencing. In addition, UPLC-Q-Exactive MS, molecular docking, and molecular dynamics simulations were employed to systematically study the active compounds of QSG.
resultsQSG treatment restored the population of RCMs and enhanced their efferocytic capacity in CHF, thereby reducing cardiomyocyte apoptosis, promoting inflammatory resolution, and improving ventricular structure and function. Mechanistically, QSG upregulated Legumain expression and activated the Arg1/Rac1 signaling axis to facilitate cytoskeletal remodeling and enhance phagocytic efficiency. Further analyses identified tanshinone IIA, neocryptotanshinone and calycosin as the core bioactive compounds of QSG. All three compounds upregulated Legumain expression and exhibited stable binding affinity toward Legumain.
conclusionQSG restores efferocytic capacity in RCMs by targeting the Legumain/Arg1/Rac1 signaling axis, thereby attenuating adverse ventricular remodeling in CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.